Market Background

Competition among new-generation incretin therapies is intensifying. The obesity and diabetes treatment market continues to grow, and companies are striving to secure market share by highlighting differentiated mechanisms. The latest candidates were highlighted at the ADA 2026 scientific session amid this trend.

Competitive Landscape

Novo Nordisk's CagriSema and Eli Lilly's retatrutide are being directly compared. Both candidates are GLP-1 receptor agonists, but they differ in structure and duration of efficacy. Experts are not yet sure which candidate will be more advantageous for long-term weight loss and blood sugar control.

Clinical Strategy

Novo's Chief Scientific Officer, Lange, emphasized that the results are still uncertain, stating, "jury still out." This means that the data from ongoing clinical trials have not yet been definitively established. Incretin therapies mimic the body's hormone function to promote insulin secretion and suppress appetite.

Investment Perspective

If both companies' next-generation candidates enter the market, they are likely to secure a premium over existing GLP-1 therapies. However, given the uncertain clinical results, investors should approach with caution. For now, it is important to closely monitor the progress of both companies' pipelines.